SYNLOGIC, INC. Proceeds from Sale and Maturity of Marketable Securities
SYNLOGIC, INC. (SYBX) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-03-12
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $0.00.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $0.00.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $25.50M, a 61.88% decline from fiscal 2023.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $66.90M, a 52.84% decline from fiscal 2022.
- SYNLOGIC, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $141.87M, a 24.42% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 3 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $7.50M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $7.50M derived: sum of 3 quarters · filed 2026-03-12 | $25.50M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $7.50M derived: sum of 2 quarters · filed 2025-11-13 | $25.50M 10-Q · filed 2025-11-13 | $30.00M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.50M 10-Q · filed 2025-08-07 | $30.00M derived: sum of 3 quarters · filed 2025-08-07 | $30.00M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $18.00M 10-Q · filed 2025-05-08 | $22.50M derived: sum of 2 quarters · filed 2025-05-08 | $22.50M derived: sum of 3 quarters · filed 2025-05-08 | $54.50M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $4.50M derived: sum of 2 quarters · filed 2025-03-06 | $36.50M derived: sum of 3 quarters · filed 2025-03-06 | $66.90M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $32.00M derived: sum of 2 quarters · filed 2024-11-12 | $62.40M 10-Q · filed 2024-11-12 | $93.90M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $62.40M 10-Q · filed 2024-08-08 | $93.90M derived: sum of 3 quarters · filed 2024-08-08 | $119.15M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $30.40M 10-Q · filed 2024-05-14 | $61.90M derived: sum of 2 quarters · filed 2024-05-14 | $87.15M derived: sum of 3 quarters · filed 2024-05-14 | $139.91M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $31.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $56.75M derived: sum of 2 quarters · filed 2024-03-19 | $109.51M derived: sum of 3 quarters · filed 2024-03-19 | $141.87M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $25.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $78.01M derived: sum of 2 quarters · filed 2023-11-09 | $110.37M 10-Q · filed 2023-11-09 | $147.12M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $52.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $85.12M 10-Q · filed 2023-08-10 | $121.87M derived: sum of 3 quarters · filed 2023-08-10 | $144.87M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $32.36M 10-Q · filed 2023-05-11 | $69.11M derived: sum of 2 quarters · filed 2023-05-11 | $92.11M derived: sum of 3 quarters · filed 2023-05-11 | $120.38M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $36.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $59.75M derived: sum of 2 quarters · filed 2023-03-29 | $88.03M derived: sum of 3 quarters · filed 2023-03-29 | $114.02M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $23.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $51.28M derived: sum of 2 quarters · filed 2022-11-10 | $77.27M 10-Q · filed 2022-11-10 | $106.37M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $28.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $54.27M 10-Q · filed 2022-08-11 | $83.37M derived: sum of 3 quarters · filed 2022-08-11 | $101.38M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $26.00M 10-Q · filed 2022-05-12 | $55.10M derived: sum of 2 quarters · filed 2022-05-12 | $73.10M derived: sum of 3 quarters · filed 2022-05-12 | $97.98M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $29.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $47.10M derived: sum of 2 quarters · filed 2022-03-17 | $71.98M derived: sum of 3 quarters · filed 2022-03-17 | $90.84M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $42.88M derived: sum of 2 quarters · filed 2021-11-10 | $61.74M 10-Q · filed 2021-11-10 | $88.06M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $24.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $43.73M 10-Q · filed 2021-08-12 | $70.05M derived: sum of 3 quarters · filed 2021-08-12 | $111.70M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $18.85M 10-Q · filed 2021-05-13 | $1.50M 10-Q · filed 2020-05-08 | $45.17M derived: sum of 2 quarters · filed 2021-05-13 | $86.82M derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $26.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $67.97M derived: sum of 2 quarters · filed 2021-03-25 | $157.47M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $41.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $131.15M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $89.50M 10-Q · filed 2020-08-06 | ||||
| 2016-09-30 | $30.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $39.90M 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | $9.00M 10-Q · filed 2016-08-15 | ||||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |